Is it time to buy more Slater & Gordon Limited?

Slater & Gordon Limited's (ASX:SGH) $890 million capital raising is larger than most IPOs likely to hit Australia in the year ahead.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Last week it was announced that Australia's largest listed law firm Slater & Gordon Limited (ASX: SGH) is to spend around $1.2 billion on the professional services division of UK business Quindell Plc assuming the deal is approved by relevant parties.

The giant deal will potentially see Slater & Gordon nearly double its market value, while the entitlement offer to raise $890 million of the funds required will probably be bigger than most of this year's standalone IPOs on the ASX.

The law firm's meteoric growth has been based on an acquisitive growth strategy in the United Kingdom, although the latest deal is its boldest yet and certainly puts Slater & Gordon higher up the risk curve as an investment opportunity, with an additional $375 million of underwritten bank debt required to fund the purchase.

Retail shareholders are being asked to take up a 2:3 renounceable entitlement offer, which will effectively add 66% to their current holding in the group.

The group's most recent half-year results showed a net profit of $33.7 million, with a cash flow from operations of $26.5 million representing 78.6% of the net profit. In the prior corresponding half-year period cash flow was 91.6% of a net profit of $21 million.

As a fast-growing personal injury (PI) business the group's accounting practices will come under scrutiny, with the posting of accruals part and parcel of operating in a world of PI claims that have notoriously long time periods to settlement (if any).

Indeed, I have personal experience of directly managing (and occasionally winning!) personal injury claims in the UK on a pro-bono basis of legal representation for individual clients from a variety of backgrounds. Time periods of 12-24 months are common until settlement and the chances of success far from guaranteed.

If liability is disputed the stakes are raised and cases can end up in court and rumble on far longer, with total compensation awarded or costs incurred (if any) unknown until a final settlement is agreed or a court order enacted.

The complexity around the posting of accruals is self-evident and Slater and Gordon's acquisition target has been a prime target of short sellers itself over allegations of improper accruals, cash flows and profit posting related to its professional services division (PSD).

Slater & Gordon says it has conducted extensive due diligence on Quindell's PSD and is 100% satisfied any issues are not material and the purchase price around 6.9x earnings is reasonable given the opportunity.

Investors in the renounceable entitlement offer will need faith in the soundness of Slater & Gordon's business model, due diligence and judgment in taking the plunge on Quindell's PSD.

At an offer price of $6.37 the stock is available at a substantial discount to the trading price ($7.85) and 15.6% discount to the theoretical ex-rights price based on the group's March 27 closing price of $7.55.

Although not over-enthusiastic about the acquisition, I'm happy to give management the benefit of the doubt and take up the offer (and some extra risk), while expecting the price to be volatile as events take their course.

Other legal eagles on the ASX include rival PI operator Shine Corporate Ltd (ASX: SHJ) and class action funder IMF Bentham Ltd (ASX: IMF), although there may be much better prospects out there if you're looking for income and growth…

Motley Fool contributor Tom Richardson owns shares in Slater & Gordon. You can find him on Twitter @tommyr345  We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policyThis article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

A white and black robot in the form of a human being stands in front of a green graphic holding a laptop and discussing robotics and automation ASX shares
Technology Shares

Joining the revolution: How I'd invest in ASX AI shares right now

Advances in artificial intelligence (AI) could usher in a new industrial revolution. Here’s how you can invest in it.

Read more »

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »